Financial Ratios

NEULAND LABORATORIES LTD.

NSE : NEULANDLABBSE : 524558ISIN CODE : INE794A01010Industry : Pharmaceuticals & DrugsHouse : Private
BSE7368.45-286.35 (-3.74 %)
PREV CLOSE ( ) 7654.80
OPEN PRICE ( ) 7748.65
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2042
TODAY'S LOW / HIGH ( )7206.10 7748.65
52 WK LOW / HIGH ( )1947 7794
NSE7368.70-287.65 (-3.76 %)
PREV CLOSE( ) 7656.35
OPEN PRICE ( ) 7590.05
BID PRICE (QTY) 7368.70 (3)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 37535
TODAY'S LOW / HIGH( ) 7202.35 7600.00
52 WK LOW / HIGH ( )1950 7790
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)127.1449.5262.5812.3812.58
   CEPS(Rs)168.2887.7493.5136.7632.74
   DPS(Rs)10.005.005.002.001.20
   Book NAV/Share(Rs)769.65650.56608.71549.21541.45
   Tax Rate(%)24.2122.2723.5069.7518.61
Margin Ratios
   Core EBITDA Margin(%)22.7814.9515.6313.308.68
   EBIT Margin(%)19.1610.0113.119.715.32
   Pre Tax Margin(%)18.078.5911.206.882.97
   PAT Margin (%)13.696.688.572.082.42
   Cash Profit Margin (%)18.1211.8412.816.186.30
Performance Ratios
   ROA(%)11.024.706.291.351.47
   ROE(%)17.907.8610.812.273.44
   ROCE(%)20.999.4412.837.843.95
   Asset Turnover(x)0.800.700.730.650.61
   Sales/Fixed Asset(x)1.281.091.221.181.26
   Working Capital/Sales(x)3.794.505.355.025.48
Efficiency Ratios
   Fixed Capital/Sales(x)0.780.910.820.850.79
   Receivable days91.3386.7479.4084.6897.96
   Inventory Days83.4198.4091.0098.63100.64
   Payable days114.73120.79115.20117.12126.08
Valuation Parameters
   PER(x)14.1520.7333.3622.9053.59
   PCE(x)10.6911.7022.337.7120.60
   Price/Book(x)2.341.583.430.521.25
   Yield(%)0.560.490.240.710.18
   EV/Net Sales(x)1.991.613.020.761.59
   EV/Core EBITDA(x)8.4410.6017.425.4817.26
   EV/EBIT(x)10.3916.0623.047.8029.84
   EV/CE(x)1.501.112.140.470.94
   M Cap / Sales1.941.382.860.481.30
Growth Ratio
   Net Sales Growth(%)25.251.5122.8414.3826.44
   Core EBITDA Growth(%)94.81-11.2454.2971.6912.45
   EBIT Growth(%)139.70-22.4965.88108.659.35
   PAT Growth(%)156.75-20.87405.63-1.6336.71
   EPS Growth(%)156.75-20.87405.63-1.63-5.33
Financial Stability Ratios
   Total Debt/Equity(x)0.120.280.220.370.33
   Current Ratio(x)1.711.571.471.421.37
   Quick Ratio(x)1.080.850.810.810.79
   Interest Cover(x)17.477.066.863.432.27
   Total Debt/Mcap(x)0.050.180.060.710.27

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.